More than just a name: "nonalcoholic fatty liver disease (NAFLD)" versus "metabolic associated fatty liver disease (MAFLD)"
Main Article Content
Article Details
Issue
Section

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int 2020;40:1254-61. doi: 10.1111/liv.14478..
Sakamoto M, Tsujikawa H, Effendi K, et al. Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Pathol Int 2017;67:1-7. doi: 10.1111/pin.12485.
Simon TG, Roelstraete B, Hartjes K, et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol 2021;75:1034-41. doi: 10.1016/j.jhep.2021.06.034.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. doi: 10.3748/wjg.v24.i30.3361.
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158: 1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312.
García-Compeán D, Jiménez-Rodríguez AR. NAFLD VS MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol 2022;27:100765. doi: 10.1016/j.aohep.2022.100765.
Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. J Hepatol 2021;74:977-9. doi: 10.1016/j.jhep.2020. 12.025.
Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74:972-4. doi: 10.1016/j.jhep.2020.10.015.
Duseja A, Taneja S. Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease – not only premature but also confusing. J Clin Exp Hepatol 2021;11:278-9. doi: 10.1016/j.jceh.2020.08. 002.
Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2022;42:277-87. doi: 10.1111/liv.15139.